FRANKFURT, April 12, 2021 (GLOBE NEWSWIRE) – Farmako GmbH, a BIP-certified pharmaceutical wholesaler with a focus on cannabinoid therapy, is initiating a collaboration with STADAPHARM GmbH to deliver THC test kits to STADAPHARM. The THC test kits developed and manufactured by Farmako in-house will be offered by STADAPHARM from April 2021 as a tool for pharmacists to carry out the identity check of medicinal cannabis flowers and extracts in a simple, fast and inexpensive way.
Farmako and STADAPHARM have signed an agreement for the supply of THC test kits. STADAPHARM GmbH, which is responsible for the specialty pharmaceuticals business within the STADA Group, will enter the medical cannabis market in the second quarter of 2021. The company will market its own THC cannabis flowers and extracts and offer the THC test kit developed and produced by Farmako along with its own products to pharmacists for the identity verification of medical cannabis.
Farmako has been supplying the THC test kit to pharmacies since December 2020. The test kit, for which Farmako has patent protection, enables a THC identity check of cannabis in just 5 minutes without the need for additional tools or expensive reference substances.It offers a simple, fast and inexpensive alternative to time-consuming and expensive thin-layer chromatography for the identity check of pharmaceuticals Ingredients or medicines that contain THC. The THC test kit has been validated by the German testing laboratory DSI-pharm, Quality Services International GmbH with regard to the specificity to prove the identity of cannabis flowers and extracts according to the German Pharmacopoeia.
Farmako has been a reliable supplier of medicinal cannabis flowers since the beginning of 2019. In the fourth quarter of 2020, the product portfolio was expanded to include pharmaceutical grade CBD isolate (GMP) as well as the THC test kit and IMC cannabis flowers. From the second quarter of 2021, Farmako will supplement its product range with its own cannabis extracts with a high THC content at a fair price.
In this way, Farmako establishes itself as a supplier with a comprehensive portfolio in the medical cannabis market and continues to present itself as a reliable partner for the retail and wholesale market.
“The discussion in the cannabis market often revolves around the high barriers for patients, suppliers, doctors and pharmacists. Therefore, at Farmako we want to facilitate access to cannabinoid therapy for patients with a high burden of suffering by providing fair prices, reliable supply and efficient service for For us, cooperation is an important element of competition. This is the only way we can develop the market for the benefit of patients. That is why we are very happy about this partnership with STADAPHARM, a renowned pharmaceutical company. “, comments Katrin Eckmans, Managing Director of Farmako GmbH.
Further information on the THC test kit:
According to § 11 of the Pharmacy Operation Regulations (ApBetrO), pharmaceutical ingredients for which an analysis / release certificate is available to confirm qualitative conformity must at least be checked for their identity. According to § 6 Paragraph 1 Clause 2 ApBetrO A pharmacy can use alternative test methods that differ from those mentioned in the German Pharmacopoeia (DAB) (ie thin-layer chromatography according to DAB “Standardized Cannabis Extract” and DAB “Cannabis Flowers”), provided the alternative is the test method delivers the same results as the methods and instruments in DAB.
Thin-layer chromatography as a method of DAB identity verification is effective, but involves a heavy workload and excessive cost. The test-only strips previously on the market did not provide effective relief as the pharmacies had to make their own test solution and use a large amount of the cannabis material for the tests – which resulted in high costs for the pharmacies and the patients.
The patented THC test kit developed by Farmako enables a very fast, validated and economical check of the THC identity with minimal time and material consumption.
The test method is based on a highly specific immunoassay THC test strip and a ready-to-use test solution (contains methanol). All the necessary test materials are already included in the test kit – only water has to be added to me. The qualitative detection of THC only requires very limited amounts of cannabis floos (5-20 mg) or cannabis extracts (1-2 drops). The test result is available within 5 minutes.
The supervision of pharmacies and the interpretation of the German pharmacopoeia lies with the health authorities, pharmacies and pharmacy councils. Since there is no uniform regulation or interpretation in the federal states, pharmacists are recommended to consult the pharmacies of the health authority regarding the identity verification of medical cannabis.
The THC test kit is patented by Farmako (German patent application no. DE102020127871).
THC test kit for pharmacies only, not for consumers.
Product contains methanol (EC no .: 200-659-6); CLP Hazard Class and Category: Flam. Liq. 2, Acute Tox. 3/3/3, STOT SE 1.
Farmako GmbH is a GDP-certified pharmaceutical wholesaler that focuses on medical cannabis and aims to facilitate access to reliable cannabinoid therapy for patients with a high level of suffering and to efficiently support members of the health professions: through fair prices, reliable product quality and the ability to do so Supply and efficient service. The company has been selling medical cannabis to pharmacies in Germany since March 2019 and is fully licensed in the UK to start distribution there in 2021. Farmako is a 100% subsidiary of AgraFlora Organics International Inc.
Further information can be found at: https://www.farmako.de/en/.
About STADA Arzneimittel AG
STADA Arzneimittel AG has its headquarters in Bad Vilbel. The company is focused on a two-pillar strategy comprised of generics, including specialty pharmaceuticals and consumer non-prescription health products. STADA Arzneimittel AG sells its products in around 120 countries worldwide. In the 2019 financial year, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA had 11,100 employees worldwide.
AgraFlora Organics International Inc. is a leading cannabis company creating shareholder value by developing revenue generating assets in the global cannabis industry. AgraFlora is primarily focused on the Canadian cannabis industry – the world’s most advanced and regulated legal cannabis market. The primary Canadian capital is Propagation Services Canada, a large commercial greenhouse in Delta, BC, focused on transforming the Canadian flower market with high-potency, low-cost cannabis. In addition, AgraFlora’s wholly owned subsidiary, Farmako GmbH, is focused on becoming Europe’s leading distributor of medical cannabis. Farmako currently has active sales activities in Germany and expects to commence active activities in the UK in 2021.
Further information on AgraFlora can be found at www.agraflora.ca and on the SEDAR profile page at www.sedar.com.
Press contact: firstname.lastname@example.org